A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Throat Spray on the Incidence and Duration of Sickness

A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Throat Spray on the Incidence and Duration of Sickness

This is a randomized, triple-blind, placebo-controlled clinical trial evaluating the effects of Beekeeper's Naturals Propolis Immune Support Throat Spray on the incidence and duration of sickness over a 16-week period. The study will enroll 100 healthy adults aged 18 to 65.

Inclusion Criteria:

• Be male or female
• Be aged 18-65
• Meet at least one of the following criteria:

Work in a hospital or other healthcare setting Work in a school

• Have a child/children under the age of 10
• Be willing to take the test or placebo product once daily and complete study questionnaires every four weeks for the 16-week study period
• Be willing to refrain from taking any over-the-counter products, herbal remedies, or supplements that target immune function during the study period and for two weeks prior.
• Be willing to maintain their current diet, sleep schedule, and activity level for the duration of the study.
• Be in good general health and not live with any uncontrolled chronic conditions.
• Reside in the United States.

Exclusion Criteria:

• Has undergone any surgeries or invasive treatments in the past six months or plans to undergo any during the study period
• Anyone with seasonal allergies
• Anyone who follows a restrictive diet (e.g., keto, vegan, raw, carnivore, etc.).
• Anyone who got a vaccination in the last 2 weeks.
• Anyone taking one or more prescription medications:

Corticosteroids: Prednisone (prednisone), Deltasone (prednisolone), Medrol (methylprednisolone), Decadron (dexamethasone), Cortef (hydrocortisone), Kenalog (triamcinolone), Flonase (fluticasone), Nasonex (mometasone) Biologics (Immunomodulating Agents): Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Stelara (ustekinumab), Cosentyx (secukinumab), Taltz (ixekizumab), Orencia (abatacept), Simponi (golimumab), Xeljanz (tofacitinib), Rituxan (rituximab), Actemra (tocilizumab), Kineret (anakinra) DMARDs (Disease-Modifying Antirheumatic Drugs): Methotrexate (methotrexate), Plaquenil (hydroxychloroquine), Arava (leflunomide), Azulfidine (sulfasalazine), Imuran (azathioprine), CellCept (mycophenolate mofetil), Cytoxan (cyclophosphamide) JAK Inhibitors: Olumiant (baricitinib), Rinvoq (upadacitinib), Jakafi (ruxolitinib) Other Immunosuppressive Medications: Prograf (tacrolimus), Neoral, Sandimmune (cyclosporine), Rapamune (sirolimus), Zortress (everolimus)

• Has had any major illness in the past three months.
• Drinks heavily (defined as 8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
• Uses illicit drugs.
• Has known allergies or hypersensitivities to any of the study product ingredients.
• Is immunocompromised due to a medical condition or due to immunosuppressive medications or treatments.
• Has any known autoimmune conditions.
• Has any chronic health conditions that could impact participation in the study, including cancer, liver, or mental health disorders.
• Has known serious allergic reactions requiring the use of an Epi-Pen.
• Is currently pregnant, trying to conceive, or breastfeeding.
• Is currently participating in another research study or plans to do so during the 16-week study period.
• Has a history of substance abuse.
• Is currently a smoker or has been a smoker in the past three months.